This patent highlight describes the synthesis and assessment of a series of new inverse agonists targeting G protein-coupled receptor 6 (GPR6) based on pyridopyrazine analogs. It details their chemical synthesis, characterization, and biological activity assays.
Li et al. (Tue,) studied this question.